We are delighted to share that eltranatamab, an immunotherapy drug, specifically known as a bispecific antibody will be made available later in 2025 for Australian myeloma patients.
2024 Cannon Family Travel Grant recipient, Dr Edward Cliff, a third-year clinical haematology registrar at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, recently attended the American Society of Haematology (ASH) Annual Meeting in California.
The Snowdome Foundation collaborates with world-leading blood cancer researchers to accelerate new therapies for Australian myeloma patients.
Supported by the Snowdome Foundation, A/Prof. Jane Oliaro is undertaking important work to improve the functionality of CAR-T cells for myeloma patients.
Snowdome co-founder and director, Prof. Miles Prince AM, received the Winsome Constance Kindness Award for his dedication to blood cancer research.
Earlier this year, the Snowdome Foundation supported a fellowship to optimise immunotherapy for aggressive lymphoma.
2022 Snowdome Haematology Fellow, Dr Josh Tobin provides an update on his research into biomarker-directed immunotherapy in advanced stage follicular lymphoma.
Gunn Family Haematology Fellowship awarded to a haematological amyloidosis research project that could accelerate clinical trials for patients with amyloidosis and related disorders.
Prof. Richard Boyd BSc (Hons) PhD Chief Scientific Advisor of Cartherics Pty Ltd provides an update on chimeric antigen receptor (CAR) cell therapy. He explains CAR T-cell and CAR Natural Killer (NK) cell therapies.